Skip to Content

Isoniazid Pregnancy and Breastfeeding Warnings

Isoniazid is also known as: Nydrazid

Isoniazid Pregnancy Warnings

Isoniazid has been assigned to a pregnancy category C by the FDA. There are no controlled data in human pregnancies. Embryocidal effects were noted in both rats and rabbits after administration of isoniazid orally during pregnancy. While cases of suspected isoniazid induced anomalies have been reported, causality is unknown and retrospective analyses have failed to document significant teratogenic risk. Isoniazid should only be given during pregnancy when need has been clearly established. The initial therapy of active tuberculosis in pregnant patients recommended by the Centers for Disease Control includes isoniazid. Isoniazid is also recommended by the American Thoracic Society. For HIV-infected women, the USPHS/IDSA (U.S. Public Health Service/Infectious Diseases Society of America) Prevention of Opportunistic Infections Working Group recommends that chemoprophylaxis be given during pregnancy to those with a positive tuberculin skin test or a history of exposure to active tuberculosis, after active disease has been ruled out. Isoniazid is the prophylactic agent of choice unless exposure to drug-resistant tuberculosis is suspected. However, the Working Group also states that "because of theoretical concerns regarding possible teratogenicity associated with drug exposures during the first trimester, providers may choose to initiate prophylaxis after the first trimester."

Isoniazid crosses the placenta. At delivery, serum cord concentrations have been reported to range from 0% to 66% of that found in maternal serum. Reports of the use of isoniazid during pregnancy generally involve multiple drug therapy. Malformations reported which have involved isoniazid use include one case each of myelomeningocele and hypospadias. The Collaborative Perinatal Project reported 85 fetal exposures to isoniazid during the first trimester. Ten malformations were reported, which was nearly twice the normal rate. However, due to the small number of exposures, no conclusion could be drawn. Hemorrhagic complications resulting from vitamin K deficiency have been reported in two infants whose mothers received antituberculous drugs. One mother had been treated with isoniazid and rifampin, and the other with isoniazid, rifampin, and ethambutol. A third infant with hemorrhagic disease had only been exposed to ethambutol and rifampin. Pleural mesothelioma was reported in a nine-year-old child whose mother received isoniazid during the second and third trimesters of pregnancy. The carcinogenicity of isoniazid has not been documented.

See references

Isoniazid Breastfeeding Warnings

Isoniazid and acetylisoniazid, a metabolite, are excreted into human milk. Following oral administration of 300 mg, approximately 7 mg was excreted in breast milk over 24 hours. While adverse effects in the nursing infant are not reported, it may be prudent to monitor the infant for signs of peripheral neuritis and hepatotoxicity. Isoniazid is considered compatible with breast-feeding by the American Academy of Pediatrics.

See references

References for pregnancy information

  1. Heinonen O, Slone D, Shapiro S; Kaufman DW ed. "Birth Defects and Drugs in Pregnancy." Littleton, MA: Publishing Sciences Group, Inc. (1977): 297
  2. Miceli JN, Olson WA, Cohen SN "Elimination kinetics of isoniazid in the newborn infant." Dev Pharmacol Ther 2 (1981): 235-9
  3. Albino JA, Reichman LB "The treatment of tuberculosis." Respiration 65 (1998): 237-55
  4. Bromberg YM, Salzberger M, Bruderman I "Placental transmission of isonicotinic acid hydrazide." Gynaecologia 140 (1955): 141-4
  5. Holdiness MR "Transplacental pharmacokinetics of the antituberculosis drugs." Clin Pharmacokinet 13 (1987): 125-9
  6. CDC "Initial therapy for tuberculosis in the era of multidrug resistance. Recommendations of the advisory council for the elimintion of tuberculosis." MMWR Morb Mortal Wkly Rep 42 (1993): 1-8
  7. Eggermont E, Logghe N, Van De CAsseye M, et al. "Haemorrhagic disease of the newborn in the offspring of rifampicin and isoniazid treated mothers." Acta Paediatr Belg 29 (1976): 87-90
  8. Lowe CR "Congenital defects among children born to women under supervision or treatment for pulmonary tuberculosis." Br J Prev Soc Med 18 (1964): 14-6
  9. Snider DE Jr, Layde PM, Johnson MW, Lyle MA "Treatment of tuberculosis during pregnancy." Am Rev Respir Dis 122 (1980): 65-79
  10. "Product Information. INH (isoniazid)." Ciba Pharmaceuticals, Summit, NJ.
  11. American Thoracic Society and the Centers for Disease Control and Prevention. "Treatment of tuberculosis and tuberculosis infection in adults and children." Am J Respir Crit Care Med 149 (1994): 1359-74
  12. Tuman KJ, Chilcote RR, Berkow RI, Moohr JW "Mesothelioma in child with prenatal exposure to isoniazid." Lancet 2 (1980): 362
  13. Medchill MT, Gillum M "Diagnosis and management of tuberculosis during pregnancy." Obstet Gynecol Surv 44 (1989): 81-4
  14. CDC. Centers for Disease Control and Prevention. "1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus." MMWR Morb Mortal Wkly Rep 48(RR-10) (1999): 1-66

References for breastfeeding information

  1. Berlin CM, Lee C "Isoniazid and acetylisoniazid disposition in human milk, saliva and plasma." Fed Proc 38 (1979): 426
  2. Snider DE, Powell KE "Should women taking antituberculosis drugs breast-feed?" Arch Intern Med 144 (1984): 589-90
  3. Committee on Drugs, 1992 to 1993 "The transfer of drugs and other chemicals into human milk." Pediatrics 93 (1994): 137-50
  4. "Product Information. INH (isoniazid)." Ciba Pharmaceuticals, Summit, NJ.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.